Literature DB >> 3513687

Efficacy and safety of topical oxymetazoline in treating allergic and environmental conjunctivitis.

E Duzman, A Warman, R Warman.   

Abstract

This randomized, double-masked study evaluated the safety and efficacy of oxymetazoline 0.025% topical ophthalmic solution compared with its vehicle when used to treat allergic or environmental conjunctivitis. Thirty-nine patients with moderate bilateral conjunctival hyperemia instilled one drop of either oxymetazoline 0.025% solution or its vehicle twice daily for one week. At each evaluation the signs and symptoms of conjunctivitis were evaluated, complete eye examinations were performed, and heart rate and blood pressure were measured. An overall assessment of treatment efficacy was made at each follow-up evaluation. The signs and symptoms of conjunctivitis had significantly improved in the oxymetazoline-treated group when compared with those of the vehicle-treated group, and the ocular and systemic safety of each treatment was comparable.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3513687

Source DB:  PubMed          Journal:  Ann Ophthalmol        ISSN: 0003-4886


  3 in total

1.  Passive and oxymetazoline-enhanced delivery with a lens device: pharmacokinetics and efficacy studies with rabbits.

Authors:  David J Miller; S Kevin Li; Anthony L Tuitupou; Rajan P Kochambilli; Kongnara Papangkorn; Donald C Mix; William I Higuchi; John W Higuchi
Journal:  J Ocul Pharmacol Ther       Date:  2008-08       Impact factor: 2.671

2.  Brimonidine Ophthalmic Solution 0.025% for Reduction of Ocular Redness: A Randomized Clinical Trial.

Authors:  Eugene McLaurin; Megan E Cavet; Paul J Gomes; Joseph B Ciolino
Journal:  Optom Vis Sci       Date:  2018-03       Impact factor: 1.973

3.  Transmissible ER stress reconfigures the AML bone marrow compartment.

Authors:  Ben Doron; Sherif Abdelhamed; John T Butler; Saman K Hashmi; Terzah M Horton; Peter Kurre
Journal:  Leukemia       Date:  2018-09-11       Impact factor: 11.528

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.